


# INFORMATION TECHNOLOGY EMPOWERING POINTS-OF-CARE

BIOSCICON, INC  
2016

## MEETING THE GOALS



10/26/2016 BIOSCICON, INC. (C) 2016 2

## MEDICINE IN OUR LIVES

- PAST**
- HELP INDIVIDUALS
  - PROTECT OTHERS
  - FAMILY DOCTOR
  - MICROENVIRONMENTAL SURVEILLANCE
- PRESENT**
- POINTS-OF-CARE**
- Recruitment/ registration
  - Informed consent
  - Exam
  - Specimen Collection
  - Digital imaging

10/26/2016 BIOSCICON, INC. (C) 2016 3

## FUTURE

- GLOBAL NETWORKING**
- TELEMEDICINE: BRIDGE TO EQUALISATION
  - STANDARD: HEALTH NEEDS, NOT ONLY HEALTHCARE DEMANDS
  - MEASURED: ROBUST CLINICAL PARAMETERS: INCIDENCE, PREVALENCE AND MORTALITY
- REVERSE DISEASE TRENDS**
- MODEL: CERVICAL CANCER
  - Pap test has made impact in the US only after the outreach of women at risk went beyond 50%
  - More that 90% were Pap test negative, but 7% Pap positive helped doctors to reduce the cervical cancer mortality for 80% - the best anticancer prevention

10/26/2016 BIOSCICON, INC. (C) 2016 4

## GLOBAL NETWORKING



10/26/2016 BIOSCICON, INC. (C) 2016 5


## WOMEN OF ALL COLORS UNITE



10/26/2016 BIOSCICON, INC. (C) 2016 6

## NEW TOOLS; TELEMEDICINE PROTOCOL FOR SERVICE DELIVERY

### MarkPap: Digital-Telecytology System




10/26/2016 BIOSCICON, INC. (C) 2016 7

## NEW TOOLS: DIGITAL WORKSTATION



10/26/2016 BIOSCICON, INC. (C) 2016 8

## MULTIPLE BIOMARKERS



10/26/2016 BIOSCICON, INC. (C) 2016 9

## DIGITAL IMAGING PRINCIPLES




Figure 6. Cell image tomography and image scan. Segmentation of a cell image using two curves for critical slicing. a. Imaging. Cell image digital within 100 x 100 pixel frame. N = nucleus, cy = cytoplasm, n = nucleolus, tp = thin nucleolus product (m - tp = scan line). b. Segments of cell image separated by slicing. S, Slowing, B = "black" curve, W = "white" curve, L, L, L, L = positions from which "white" curve slices cell image. I = cytoplasmic density. II = selection of nucleolus. III = selection of NP and cell domains.


10/26/2016 BIOSCICON, INC. (C) 2016 10

## NEW COLLECTION DEVICES




10/26/2016 BIOSCICON, INC. (C) 2016 11

## SERVICE EVOLUTION




10/26/2016 BIOSCICON, INC. (C) 2016 12

## POINTS-OF-CARE



10/26/2016 BIOSCICON, INC. (C) 2016 13

## NETWORK MANAGEMENT OF A CASE




10/26/2016 BIOSCICON, INC. (C) 2016 14

## IMAGE ACQUISITION UNIT




10/26/2016 BIOSCICON, INC. (C) 2016 15

## BIOMARKER CONTROL SLIDE




10/26/2016 BIOSCICON, INC. (C) 2016 16

## IMAGE EVALUATION UNIT




10/26/2016 BIOSCICON, INC. (C) 2016 17

## CERVICAL CANCER




10/26/2016 BIOSCICON, INC. (C) 2016 18

## HUBS FOR GLOBAL NETWORKING



10/26/2016 BIOSCICON, INC. (C) 2016 19

## FUTURE TELEMEDICINE IN CHINA



10/26/2016 BIOSCICON, INC. (C) 2016 20

## PROSPECTIVE OF NEW MEDICINE



10/26/2016 BIOSCICON, INC. (C) 2016 21

## SPONSOR OF THIS DEVELOPMENT



WWW.BIOSCICON.COM

10/26/2016 BIOSCICON, INC. (C) 2016 22